Financhill
Sell
32

JANX Quote, Financials, Valuation and Earnings

Last price:
$30.44
Seasonality move :
-14.22%
Day range:
$30.09 - $31.95
52-week range:
$28.92 - $71.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
125.34x
P/B ratio:
1.76x
Volume:
537.1K
Avg. volume:
862.9K
1-year change:
-22.23%
Market cap:
$1.8B
Revenue:
$10.6M
EPS (TTM):
-$1.28

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
JANX
Janux Therapeutics
$1.3M -$0.45 -68.05% -30.48% $87.85
AMGN
Amgen
$8.9B $5.08 8.14% 257.4% $315.95
FBIO
Fortress Biotech
$16.3M -$0.75 -9.13% -41.51% $15.33
HEPA
Hepion Pharmaceuticals
-- -- -- -- --
INVA
Innoviva
$92.6M $0.41 3.55% -46.05% $19.00
VKTX
Viking Therapeutics
-- -$0.27 -- -21.87% $99.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
JANX
Janux Therapeutics
$30.43 $87.85 $1.8B -- $0.00 0% 125.34x
AMGN
Amgen
$315.04 $315.95 $169.2B 41.73x $2.38 2.9% 5.09x
FBIO
Fortress Biotech
$1.70 $15.33 $46.9M -- $0.00 0% 0.33x
HEPA
Hepion Pharmaceuticals
$0.83 -- $895.3K -- $0.00 0% --
INVA
Innoviva
$17.21 $19.00 $1.1B 90.58x $0.00 0% 3.81x
VKTX
Viking Therapeutics
$30.07 $99.29 $3.4B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
JANX
Janux Therapeutics
-- -5.160 -- 38.58x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
FBIO
Fortress Biotech
71.75% 0.988 900.37% 0.99x
HEPA
Hepion Pharmaceuticals
-- 2.743 -- --
INVA
Innoviva
39.35% 0.641 41.24% 2.11x
VKTX
Viking Therapeutics
-- -1.225 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
JANX
Janux Therapeutics
-- -$29M -11.37% -11.37% -8164.47% -$16.8M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
FBIO
Fortress Biotech
$9.3M -$22.1M -94.06% -- -166.72% -$20.1M
HEPA
Hepion Pharmaceuticals
-- -$4.5M -- -- -- -$2.5M
INVA
Innoviva
$84.6M $43.1M 2.07% 3.44% 32.07% $55.2M
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$31.2M

Janux Therapeutics vs. Competitors

  • Which has Higher Returns JANX or AMGN?

    Amgen has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 6.9%. Janux Therapeutics's return on equity of -11.37% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    JANX
    Janux Therapeutics
    -- -$0.36 $656.1M
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About JANX or AMGN?

    Janux Therapeutics has a consensus price target of $87.85, signalling upside risk potential of 184.89%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 0.29%. Given that Janux Therapeutics has higher upside potential than Amgen, analysts believe Janux Therapeutics is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    JANX
    Janux Therapeutics
    12 1 0
    AMGN
    Amgen
    9 14 2
  • Is JANX or AMGN More Risky?

    Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock JANX or AMGN?

    Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.9% to investors and pays a quarterly dividend of $2.38 per share. Janux Therapeutics pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios JANX or AMGN?

    Janux Therapeutics quarterly revenues are $439K, which are smaller than Amgen quarterly revenues of $9.1B. Janux Therapeutics's net income of -$20.2M is lower than Amgen's net income of $627M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 41.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 125.34x versus 5.09x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    JANX
    Janux Therapeutics
    125.34x -- $439K -$20.2M
    AMGN
    Amgen
    5.09x 41.73x $9.1B $627M
  • Which has Higher Returns JANX or FBIO?

    Fortress Biotech has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -87.96%. Janux Therapeutics's return on equity of -11.37% beat Fortress Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    JANX
    Janux Therapeutics
    -- -$0.36 $656.1M
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
  • What do Analysts Say About JANX or FBIO?

    Janux Therapeutics has a consensus price target of $87.85, signalling upside risk potential of 184.89%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 801.96%. Given that Fortress Biotech has higher upside potential than Janux Therapeutics, analysts believe Fortress Biotech is more attractive than Janux Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    JANX
    Janux Therapeutics
    12 1 0
    FBIO
    Fortress Biotech
    1 0 0
  • Is JANX or FBIO More Risky?

    Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.750, suggesting its more volatile than the S&P 500 by 74.992%.

  • Which is a Better Dividend Stock JANX or FBIO?

    Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.

  • Which has Better Financial Ratios JANX or FBIO?

    Janux Therapeutics quarterly revenues are $439K, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Janux Therapeutics's net income of -$20.2M is lower than Fortress Biotech's net income of -$12.9M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 125.34x versus 0.33x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    JANX
    Janux Therapeutics
    125.34x -- $439K -$20.2M
    FBIO
    Fortress Biotech
    0.33x -- $14.6M -$12.9M
  • Which has Higher Returns JANX or HEPA?

    Hepion Pharmaceuticals has a net margin of -6391.57% compared to Janux Therapeutics's net margin of --. Janux Therapeutics's return on equity of -11.37% beat Hepion Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    JANX
    Janux Therapeutics
    -- -$0.36 $656.1M
    HEPA
    Hepion Pharmaceuticals
    -- -$0.72 --
  • What do Analysts Say About JANX or HEPA?

    Janux Therapeutics has a consensus price target of $87.85, signalling upside risk potential of 184.89%. On the other hand Hepion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 180840.89%. Given that Hepion Pharmaceuticals has higher upside potential than Janux Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Janux Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    JANX
    Janux Therapeutics
    12 1 0
    HEPA
    Hepion Pharmaceuticals
    0 0 0
  • Is JANX or HEPA More Risky?

    Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hepion Pharmaceuticals has a beta of 1.625, suggesting its more volatile than the S&P 500 by 62.537%.

  • Which is a Better Dividend Stock JANX or HEPA?

    Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hepion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Hepion Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios JANX or HEPA?

    Janux Therapeutics quarterly revenues are $439K, which are larger than Hepion Pharmaceuticals quarterly revenues of --. Janux Therapeutics's net income of -$20.2M is lower than Hepion Pharmaceuticals's net income of -$4.9M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Hepion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 125.34x versus -- for Hepion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    JANX
    Janux Therapeutics
    125.34x -- $439K -$20.2M
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$4.9M
  • Which has Higher Returns JANX or INVA?

    Innoviva has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 22.15%. Janux Therapeutics's return on equity of -11.37% beat Innoviva's return on equity of 3.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    JANX
    Janux Therapeutics
    -- -$0.36 $656.1M
    INVA
    Innoviva
    92.2% $0.26 $1.1B
  • What do Analysts Say About JANX or INVA?

    Janux Therapeutics has a consensus price target of $87.85, signalling upside risk potential of 184.89%. On the other hand Innoviva has an analysts' consensus of $19.00 which suggests that it could grow by 10.4%. Given that Janux Therapeutics has higher upside potential than Innoviva, analysts believe Janux Therapeutics is more attractive than Innoviva.

    Company Buy Ratings Hold Ratings Sell Ratings
    JANX
    Janux Therapeutics
    12 1 0
    INVA
    Innoviva
    0 1 0
  • Is JANX or INVA More Risky?

    Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innoviva has a beta of 0.564, suggesting its less volatile than the S&P 500 by 43.648%.

  • Which is a Better Dividend Stock JANX or INVA?

    Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios JANX or INVA?

    Janux Therapeutics quarterly revenues are $439K, which are smaller than Innoviva quarterly revenues of $91.8M. Janux Therapeutics's net income of -$20.2M is lower than Innoviva's net income of $20.3M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Innoviva's PE ratio is 90.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 125.34x versus 3.81x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    JANX
    Janux Therapeutics
    125.34x -- $439K -$20.2M
    INVA
    Innoviva
    3.81x 90.58x $91.8M $20.3M
  • Which has Higher Returns JANX or VKTX?

    Viking Therapeutics has a net margin of -6391.57% compared to Janux Therapeutics's net margin of --. Janux Therapeutics's return on equity of -11.37% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    JANX
    Janux Therapeutics
    -- -$0.36 $656.1M
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About JANX or VKTX?

    Janux Therapeutics has a consensus price target of $87.85, signalling upside risk potential of 184.89%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 230.21%. Given that Viking Therapeutics has higher upside potential than Janux Therapeutics, analysts believe Viking Therapeutics is more attractive than Janux Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    JANX
    Janux Therapeutics
    12 1 0
    VKTX
    Viking Therapeutics
    9 1 0
  • Is JANX or VKTX More Risky?

    Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

  • Which is a Better Dividend Stock JANX or VKTX?

    Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios JANX or VKTX?

    Janux Therapeutics quarterly revenues are $439K, which are larger than Viking Therapeutics quarterly revenues of --. Janux Therapeutics's net income of -$20.2M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 125.34x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    JANX
    Janux Therapeutics
    125.34x -- $439K -$20.2M
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roblox Stock a Buy, Sell or Hold?
Is Roblox Stock a Buy, Sell or Hold?

Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…

Is Shopify a Millionaire Maker?
Is Shopify a Millionaire Maker?

Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…

Is Alphabet Stock No Longer a Good Bet?
Is Alphabet Stock No Longer a Good Bet?

Alphabet tripled its price per share over the past 5…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
95
EXOD alert for Mar 21

Exodus Movement [EXOD] is up 17.89% over the past day.

Buy
58
SIG alert for Mar 21

Signet Jewelers [SIG] is down 0.64% over the past day.

Sell
43
HQY alert for Mar 21

HealthEquity [HQY] is up 0.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock